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A Mass Spectrometry Survey of Chromatin-Associated
Proteins in Pluripotency and Early Lineage Commitment
Guido van Mierlo,* Roelof Alexander Wester, and Hendrik Marks*
Pluripotency can be captured in vitro in the form of Embryonic Stem Cells
(ESCs). These ESCs can be either maintained in the unrestricted “na¨ıve” state
of pluripotency, adapted to developmentally more constrained “primed”
pluripotency or diﬀerentiated towards each of the three germ layers.
Epigenetic protein complexes and transcription factors have been shown to
specify and instruct transitions from ESCs to distinct cell states. In this study,
proteomic proﬁling of the chromatin landscape by chromatin enrichment for
proteomics (ChEP) is used in mouse naive pluripotent ESCs, primed
pluripotent Epiblast stem cells (EpiSCs), and cells in early stages of
diﬀerentiation. A comprehensive overview of epigenetic protein complexes
associated with the chromatin is provided and proteins associated with the
maintenance and loss of pluripotency are identiﬁed. The data reveal major
compositional alterations of epigenetic complexes during priming and
diﬀerentiation of na¨ıve pluripotent ESCs. These results contribute to the
understanding of ESC diﬀerentiation and provide a framework for future
studies of lineage commitment of ESCs.
Pluripotency is a transient state during embryonic development
in which cells in the epiblast are capable of forming all somatic
cell types and germ cells.[1] After implantation in the uterus,
pluripotent cells progressively gain restrictive epigenetic features
that constrain their developmental potential.[2] This resulted in
the dogma that there is no single pluripotent state, but rather a
spectrum of pluripotent states ranging from “na¨ıve” to “primed,”
with themajor discriminator being that primed Embryonic Stem
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Cells (ESCs) are receptive to
diﬀerentiation-inducing cues from
the environment.[3,4] Several distinct
populations of pluripotent cells can
be maintained in vitro, each reﬂecting
a particular time point in embryonic
development.[2] Na¨ıve ESCs of mice
can be derived from pre-implantations
embryos and can be maintained in fetal
calf serum supplemented with Leukemia
Inhibitory Factor (LIF),[5,6] whichmediate
activation of the SMAD and JAK-STAT
signaling, respectively.[2] Upon injection
into pre-implantation embryos, these
cells can contribute to all germ layers
and the germline.[3] The in vitro cultured
equivalents of post-implantation pluripo-
tent cells are Epiblast stem cells (EpiSCs),
of which the maintenance relies on stim-
ulation of SMAD and ERK signaling
by Activin A and FGF2, respectively.[7,8]
EpiSCs are more developmentally
constrained and represent the “primed” state of pluripotency,
as EpiSCs are not germline-competent and do not contribute
eﬃciently to embryos in chimaera assays.[9,10] However, EpiSCs
retain the ability to form teratomas, demonstrating their
pluripotency,[8] although EpiSCs cannot revert to the na¨ıve state
of pluripotency. When primed ESCs progress with dissolution of
the pluripotent state, they initiate lineage speciﬁcation programs
during diﬀerentiation and as such are no longer considered
pluripotent.[11]
The transition from naive to primed and subsequently dif-
ferentiation requires extensive rewiring of the cellular state, ex-
empliﬁed by major changes in cell morphology and distinct
metabolic, transcriptional and epigenetic states.[12] Some of these
changes, such as the activation of lineage-priming genes and
increase of DNA methylation, are readily initiated in primed
pluripotency.[13,14] Another notable example comprises bivalent
chromatin domains, which are decorated with both repressive
and activating histone marks,[15] that are largely resolved when
the pluripotent state is lost, starting upon priming of ESCs.[16]
Epigenetic processes play a substantial role in regulation of
cell fate decisions. The eﬀector proteins on the chromatin, Tran-
scription Factors (TFs), often exhibit a role as "master regulator"
by binding to and regulating many genes, thereby driving cell
state transitions.[17] Despite their low abundance, transcription
factors make up a signiﬁcant portion of the variation in the
mammalian proteome,[18] and exert critical roles in mammalian
development.[17] Several regulatory TFs have been discovered that
drive early priming or diﬀerentiation in the embryo, such as Otx2
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Figure 1. Generation of distinct cell types using speciﬁc culture conditions. A) Schematic overview of the culture conditions and workﬂow used. B)
Colonies of the various cell types as used in this study. C) Gene expression for selected markers to validate the distinct molecular signature. Error bars
represent SEM, n = 2.
and Zeb1/2, respectively.[19] In addition, recent reports have high-
lighted dramatic rewiring of epigenetic complexes between ESCs
and early diﬀerentiated cell types such as neural progenitor cells
(NPCs).[20,21] However, a comprehensive overview of the chro-
matin environment during priming and diﬀerentiation is cur-
rently lacking. Such an overviewwould provide valuable informa-
tion on TFs and other epigenetic factors in the process of diﬀer-
entiation. Here, we set out to provide a comprehensive overview
of the chromatin proteome during the onset of diﬀerentiation.
As epigenetic factors and TFs are generally lowly abundant,[18]
their detection is challenging when using proteomics approaches
that proﬁle total cell lysates.[22] However, these factors can be
brought into the dynamic range of mass spectrometer through
enrichment of the chromatin fraction.[23–26] Simultaneously, this
provides information on the levels of these factors in their rel-
evant context.[27,28] To gain insight in dynamics of epigenetic
regulators and transcription factors during pluripotency and
diﬀerentiation, we collected a range of cell types representing
na¨ıve pluripotency (“ESCs”), primed pluripotency (”EpiSCs”),
and early neuronal diﬀerentiation (“END”), which is a widely
adopted diﬀerentiation system [29] (Figure 1A). First, we con-
ﬁrmed that the various cell types were morphologically dis-
tinct. In particular, ESCs formed small colonies, EpiSCs formed
large, ﬂatter colonies, and END cells were hallmarked by a more
stretched morphology[30] (Figure 1B). In terms of expression of
known marker genes, the na¨ıve pluripotency marker Rex1 was
highly expressed in ESCs, but not in other cell types. EpiSC cul-
ture conditions showed high expression of EpiSC markers Otx2,
Fgf5, and Zic2.[31] Ectodermal diﬀerentiation markers Pax6 and
Sox1 were upregulated in END cells (Figure 1C).[31] These results
validated our in vitro diﬀerentiation protocol.
Next, we aimed to isolate the chromatin of these cells using
Chromatin Enrichment for Proteomics (ChEP)[23] (Figure 2A).
To conﬁrm that ChEP enriches for chromatin, we validated the
enrichment for histones after ChEP of ESCs as compared
to whole cell extracts of ESCs using Coomassie staining
(Figure S1A, Supporting Information). Next, we generated
chromatin proteomes of ESCs and compared these to whole
cell proteomes of ESCs. We observed that the ChEP strongly en-
riches for chromatin factors such as histones and DNA binding
zinc ﬁnger proteins, while ChEP depletes for cytosolic factors
such as mitochondria and translation initiation factors (Figure
S1B-D), validating the ChEP procedure. Next, we performed
ChEP for ESCs, EpiSCs, and END cells and performed mass
spectrometry analyses of the chromatin fraction. A total of 4174
proteins were reproducibly quantiﬁed (Figure S1E, Supporting
Information) and the replicates showed a high correlation
(spearman correlation >0.95) (Figure 2B,C). Next, as chromatin
enrichment procedures can be prone to contamination from
organelles such as the mitochondria,[32] we assessed the purity
of the ChEP proteomes on the peptide level. This revealed that of
all detected proteins, 70% (ESCs), 60% (EpiSCs), and 63% (END
cells) of the unique and razor peptides originated from proteins
with an expected chromatin function.[33] For further downstream
analysis, only the proteins with an expected chromatin function
(Experimental Section; Table S2, Supporting Information) were
included.
For validation of the cell types on the chromatin level, we
plotted the Label Free Quantiﬁcation (LFQ) values of known
markers of EpiSCs and early diﬀerentiation, which included
na¨ıve markers (TBX3 and KLF4), priming markers (DNMT3B
and GRHL2), and neuronal markers (FOXP1 and HMGN3)
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Figure 2. ESCs, EpiSCs and END cells show distinct chromatin proteome signatures. A) Schematic overview of workﬂow that was applied for ChEP-MS.
B) Spearman correlation of all ChEP samples. C) Scatter plot of two replicas of ESC chromatin proteomes. Spearman correlation is indicated in the
plot. D) log2 LFQ values for proteins associated with diﬀerent cell states: TBX3 and KLF4 with na¨ıve pluripotency, DNMT3B and GRHL2 with primed
pluripotency, and FOXP1 and HMGN3 with neuronal development. E) Heatmap showing all diﬀerential proteins (ANOVA, BH-corrected FDR<0.05)
clustered on z-score. Number of proteins per cluster is marked, relevant GO terms associated with each cluster are mentioned.
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(Figure 2D). Of all proteins included in the analysis, ANOVA
statistics revealed 659 proteins to be signiﬁcantly diﬀerentially
abundant between the three cell types. We clustered these pro-
teins using k-means clustering. This approach revealed distinct
clusters with GO terms associated with their particular cell state.
Notable examples include the term “telomere maintenance” be-
ing enriched on the chromatin in ESCs, whereas END chromatin
was enriched with factors associated with neuro-ectodermal
processes such as “neurogenesis” and ‘regulation of epithelial
cell diﬀerentiation’ (Figure 2E).
After validation of the samples, we aimed to provide a
comprehensive overview of the abundance of major epigenetic
complexes on the chromatin in these cells. Notably, we pre-
viously showed that the abundance of chromatin-associated
proteins is in good correspondence to the levels of the respective
proteins as observed in protein complexes using protein complex
pulldowns.[34] We focused on major epigenetic protein com-
plexes including the Polycomb Repressive Complex 2 (PRC2),
Nucleosome Remodeling and Deacetylase (NuRD) Complex, and
the Brg/Brahma-associated factors (BAF) complex. We observed
large changes within these epigenetic complexes (Figure 3A).
For example, we observed a downregulation of many PRC2
components including the core complex consisting of EED,
EZH2, and SUZ12, which we also validated using western blot
for EED (Figure S1F, Supporting Information). This observation
is in line with previous reports highlighting a major rewiring of
the PRC2 complex during diﬀerentiation resulting in a strong
reduction of many components in neural progenitor cells.[20,35]
The BAF complex is known to change composition during
diﬀerentiation.[36] In line, we observed an increase of subunits
that characterize neuronal diﬀerentiation (npBAF) such as
SMARCC2 in EpiSCs, and these levels increase to a larger extent
in END cells. In contrast, subunits that deﬁne the ESC version
of the BAF complex (esBAF; SMARCC1, SMARCD2, and
ACTL6A) remain at similar levels while exiting the na¨ıve state,[36]
indicating a balance shift toward npBAF, although the esBAF
complex remains present as well. In addition, several other BAF
complex subunits display strong dynamics upon diﬀerentiation.
For example, SMARCA4 (also known as BRG1) is strongly
upregulated in END cells, which is likely related to the require-
ment of SMARCA4 for induction of enhancers during lineage
commitment.[37] On the other hand, SS18 seems to be mainly
present in pluripotency, which could indicate that the embryonic
lethality observed in mice lacking SS18 is readily caused by de-
fects in very early embryonic development.[38] Finally, we focused
on the NuRD complex as a very recent report suggested altered
NuRD complex composition in ESCs and NPCs.[21] In line with
this previous report, we observe more ZFP296 on chromatin in
ESCs and more ZMYND8 and ZNF687 on chromatin during
early diﬀerentiation. Interestingly, some changes such as the
gain of ZMYND8 are readily present in EpiSCs, indicating this
switch occurs during pluripotency (Figure 3A, S1G), whereas the
increase of CHD3 andMBD2mainly occurs after the pluripotent
state is lost. As such, these results further indicate that NuRD
changes composition upon ESC diﬀerentiation.
Next, we focused on DNAmethylation as this is a major driver
of diﬀerentiation.[39] We observed higher levels of DNMT3B
in EpiSCs, in line with previous reports,[40] but an increase in
DNMT3A in END cells (Figure 3A), which could indicate a switch
in DNMT3 proteins during initiation of diﬀerentiation. We also
observed a drastic downregulation TET1/2 in both EpiSCs and
END cells, which ﬁts previous reports showing the downreg-
ulation of TET1/2 during embryoid body diﬀerentiation.[41] In
addition, this further indicates that the altered DNA methylation
landscape in diﬀerentiating cells may be the result of a shift
in TET1/2 and DNMT3A/B balance, rather than a unilateral
increase in depositing enzymes.[39,42]
The last category of proteins we focused on is pluripotency fac-
tors as these comprise dynamic regulators of cell fate and dif-
ferentiation. We observed that both EpiSCs and END cells dis-
played an overall downregulation of pluripotency markers, ﬁt-
ting the loss of the na¨ıve state (Figure S1H, Supporting Informa-
tion). In addition, EpiSCs were characterized by increased levels
of LIN28A/B which is characteristic for primed pluripotency [43]
(Figure S1H). Collectively, our analysis reveals strong rewiring
of chromatin-associated epigenetic complexes upon induction of
diﬀerentiation.
Finally, we aimed to use our chromatin proteomes to identify
candidate TFs that regulate diﬀerentiation. We ﬁltered the pro-
teins identiﬁed in the chromatin proteomes for TF activity using
a combination of published TF databases [44,45] and identiﬁed dif-
ferential TFs (p < 0.05 and>twofold diﬀerence) relative to ESCs.
These analyses identiﬁed known na¨ıve pluripotency factors such
as ESRRB and KLF2 to be more abundant in ESCs (Figure 3B).
Conversely, factors associated with neural development such as
FOXC1/2 and ZEB1 are enriched in END cells,[46,47] and prim-
ing factors such as GRHL2 and LIN28B in EpiSCs.[43,48] Next to
identiﬁcation of known regulators, we identify several TFs such
as SMAD2, ZFHX3, HIC1, and ZHX2 that could be candidate
regulators for priming or diﬀerentiation.
Here, we here provide a comprehensive overview of the chro-
matin during transition from the na¨ıve pluripotent state toward
primed and diﬀerentiating cell-states. Focusing on the chromatin
proteome enabled detection of low abundant transcription fac-
tors, which allowed us to eﬀectively explore these regulatory fac-
tors during maintenance and exit of pluripotency. Several of the
changes in the chromatin protein landscape during diﬀerentia-
tion as observed in the current study are complementary to previ-
ous work [34] in which we compared two diﬀerent states of na¨ıve
pluripotency, represented by 2i ESCs and serum ESCs. An ex-
ample comprises PRC2, which is moderately downregulated in
the transition from 2i to serum ESCs, and more drastically upon
diﬀerentiation. This suggests that epigenetic changes that are
linked to diﬀerentiation are readily initiated upon dissolution of
the pluripotent ground state.
In conclusion, the dataset as generated in the current study
recapitulates known dynamics in epigenetic protein complexes
during diﬀerentiation and can be used to identify novel candidate
proteins for future studies. To facilitate this, we have included
an extensive table with the proteins identiﬁed in this study, their
abundance, and whether they are signiﬁcantly diﬀerent between
ESCs, EpiSCs, and END cells. In addition, we have highlighted
whether a protein is considered a chromatin factor (Table S2,
Supporting Information). Overall, these data provide a useful re-
source for future studies on the chromatin environment during
maintenance and exit of pluripotency.
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Figure 3. Rewiring of epigenetic complexes A) Log2 fold change (relative to ESCs) of epigenetic complexes and DNA methylation associated factors in
both EpiSCs and END cells. B) Candidate regulators of priming and diﬀerentiation. Proteins of interest with p< 0.05 (ANOVA) and>twofold diﬀerential
have been highlighted. Further details on signiﬁcant proteins not labelled by name are present in Table S2, Supporting Information.
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Experimental Section
Cell Culture and Diﬀerentiation: Mouse ESCs were obtained from
The Global Bioresource Center ATCC (www.atcc.org) and cultured in
DMEM supplemented with 15% Fetal Bovine serum (Hyclone), 1000 U
mL−1 Lif (Merck), β-mercaptoethanol and Sodium Pyruvate. Cells were
passaged every 2–3 days using Trypsin-EDTA (Gibco, cat. no 25300120).
Mycoplasm was conﬁrmed to be absent in the cell cultures. Epiblast Stem
Cells were generated by culturing ESCs in NDiﬀ medium supplemented
with 5 ng/µL FGF5 (Peprotech, cat. no 100–18B) and 8 ng µL−1 Activin
A (R&D Systems, cat. no 338-AC) for 5 days, after which cells were pas-
saged in clumps every 2–3 days using collagenase type II (Worthington,
cat. no LS004176).[49] Neuro-ectoderm diﬀerentiation was induced by
adapting serum-grown ESCs to NDiﬀ without any further supplements
for at least 7 days. Cells were split 1:1 using Accutase (Gibco, cat. no
A11105-01).
Chromatin Enrichment for Proteomics: Chromatin was harvested and
enriched as described in Kustatscher et al.[23] Cells were cross-linked on
plates using 1% formaldehyde and incubated at 37 °C for 10 min. Cross-
linking reaction was stopped by adding glycine to a concentration of
0.25 M for 5 min. Plates were rinsed with Phosphate Buﬀered Saline (PBS)
and scraped in 5–10 mL of PBS into tubes. Tubes were centrifuged at
1000 g for 3 min, supernatant was aspirated and cells were resuspended
and homogenized in 1 mL cold lysis buﬀer (25 mm TRIS pH 7.4, 0.1%
Triton X-100, 85 mm KCl, 1X Roche protease inhibitor). Suspensions were
centrifuged at 2300 g for 5 min at 4 °C, supernatant was aspirated and
pellets were resuspended in 500 µL of lysis buﬀer and incubated at 37 °C
for 15 min. Suspensions were centrifuged at 2300 g for 10 min at 4 °C,
supernatant was aspirated, pellets were resuspended in 500 µL of SDS
buﬀer (10 mm TRIS pH 7.4, 10 mm EDTA, 4% SDS, 1X Roche protease
inhibitor) and incubated at room temperature for 10 min. 1.5 mL of urea
buﬀer (10 mm TRIS pH 7.4, 1 mm EDTA, 8 m urea) was mixed with sam-
ples and they were centrifuged at 16 100 g for 30min at room temperature.
Supernatant was aspirated and pellets were resuspended in 500 µL SDS
buﬀer, after which 1.5 mL urea buﬀer was added and suspensions were
centrifuged at 16 100 g for 25 min at room temperature, this step was
performed twice. The supernatant was aspirated and pellets were resus-
pended in 500 µL SDS buﬀer, after which 1.5 mL SDS buﬀer was added
and suspensions were centrifuged at 16 100 g for 25 min at room temper-
ature. Supernatant was discarded and pellets were carefully resuspended
in 100–200 µL of storage buﬀer (10 mm TRIS pH 7.4, 1 mm EDTA, 25 mm
NaCl, 10% glycerol, 1X Roche protease inhibitor) and sonicated for 6 min
at high intensity (30 s on/oﬀ alternation) on a NGS bioruptor (Diagen-
ode). Protein concentration was determined using a Qubit assay (Invitro-
gen). Samples were subjected to mass spectrometry sample preparation
or western blot.
Western Blot: ChEP samples were diluted in 4X SDS buﬀer (10%
SDS, 10 mm β-mercaptoethanol, 20% glycerol, 200 µm TRIS-HCl pH
6.8, 0.05% bromophenolblue) and incubated at 95 °C for 30 min to
reverse cross-linking. Samples were loaded onto a 8% or 12% acrylamide
separating gel (3.2 mL H2O, 4 mL acrylamide, 2.6 mL 1.5 m TRIS pH 8.8,
200 µL 10% SDS, 200 µL 10% ammonium persulfate (AP), 20 µL TEMED)
topped with stacking gel (2.975 mL H2O, 1.25 mL 0.5 m TRIS-HCl pH 6.8,
50 µL 10% SDS, 670 µL acrylamide, 50 µL 10% AP, 5 µL TEMED). This
was blotted on Polyvinylidene diﬂuoride (PVDF) membranes and blocked
for 1 h in 5% milk in TBST. Membranes were then incubated in 2.5%
milk in TBST containing primary antibody o/n at 4 °C. Primary antibodies
used are anti-ZMYND8 (Atlas, Cat# HPA020949), anti-H3 (Abcam,
Cat# 1791), and anti-EED (Millipore, Cat# 09–774). After washing with
TBST, membranes were incubated in 2.5% milk in TBST containing
Horse Radish Peroxidase (HRP) conjugated secondary antibody (for
rabbit: Dako, cat. no P0161; for mouse: Dako, cat. no P0217) for 1 h at
room temperature. Antibodies were visualized via chemiluminescence
(SuperSignal West Pico Plus, Thermo Fisher).
RT-qPCR: Cell pellets were generated by taking a small volume of
cells in suspension and centrifuging samples for 3 min at 1000 g. RNA
was extracted using the RNeasy Mini Kit (Qiagen). cDNA was synthesized
by reverse transcription as previously described.[50] Quantitative PCR on
the cDNA was performed using SYBR Green (Bio-Rad, cat. no 1708886).
Primers are listed in Table S1, Supporting Information.
Mass Spectrometry Sample Preparation: Sample preparation for mass
spectrometry was adapted from published methods.[51] All centrifugation
steps were performed at 20 °C unless speciﬁed otherwise. Cross-linked
samples were incubated at 95 °C for 30 min in decrosslink buﬀer (10.5 µm
TRIS pH 8.8, 1.95% SDS, 60 µm β-mercaptoethanol). After decrosslink-
ing, 20 µg of protein in 30 µL volume was loaded onto Centrifugal Filters
(Microcon, cat. no MRCF0R030) and 200 µL of UA (8 m urea, 0.1 m
HEPES pH 8.5) was added. This was centrifuged for 15 min at 14 000 g.
Another 200 µL of UA was added, and the same centrifugation step was
applied. 100 µL fresh IAA (0.05 m iodoacetamide (IAA) in UA) was added
to samples, and this was mixed in a thermo-mixer for 1 min, after which it
was incubated for 20 min in the dark. Samples were then centrifuged for
10 min at 14 000 g. To wash, 100 µL of UA was added and samples were
centrifuged for 15 min at 14 000 g. The wash step was repeated twice. Fil-
ters were washed with 100 µL ABC (0.05 m ammonium bicarbonate) and
spun for 10 min at 14 000 g. The wash step with ABC was performed three
times. Filters were then transferred to a new collecting tube, and 40 µL of
ABC with trypsin (1:100 enzyme to protein ratio) was loaded onto the ﬁlter.
This wasmixed at 600 rpm in a thermo-mixer for 1 min. Filters were sealed
with paraﬁlm to prevent evaporation and incubated at 37 °C o/n. After
trypsin digestion, ﬁlters were centrifuged for 10 min at 14 000 g. 50 µL of
0.5 m NaCl was added and ﬁlters were centrifuged for 10 min at 14 000 g.
4 µL of triﬂuoroacetic acid (TFA) was added to acidify samples. Samples
were then subjected to stage tip preparation. Stage tips were generated by
stacking 200 µL pipet tips with three layers of C18. Tips were washed with
100 µL MeOH and spun for 2 min at 2500 g, washed with 100 µL Buﬀer B
(80% acetonitrile, 0.1% formic acid in H2O) and spun for 2 min at 2500 g
and washed with 200 µL Buﬀer A (0.1% formic acid in H2O) and spun
for 4 min at 2500 g. Samples were loaded onto stage tips and centrifuged
for 4 min at 1500 g. Tips were washed with 100 µL Buﬀer A and spun for
2 min at 2500 g, which was repeated once. Samples were then eluted in
40 µL Buﬀer B, speedvacced to 5 µL, and ﬁlled up to 12 µL with buﬀer A.
Mass Spectrometry Analysis: 5 µL digested peptides was injected into
an Easy-nLC1000 (Thermo) connected online to an LTQ-Orbitrap-Fusion
mass spectrometer (Thermo) by developing a gradient from 7 to 30%
Buﬀer B for 214 min before washes at 60% then 95% Buﬀer B, for 240 min
of total data collection time. The ﬂow rate was 250 nL min−1. Full MS
scans were collected from 400 to 1500 m/z with an Orbitrap resolution of
120 000 and an AGC target of 3e5. MS/MS spectra were recorded in the
Ion trap using higher-energy collision dissociation fragmentation. The ion
trap scan rate was set at Rapid. An AGC target of 2e4 was used with HCD
collision energy at 30% and an intensity threshold of 1e4. Scans were
recorded in data-dependent top-speed mode of a 3-s cycle with dynamic
exclusion set at 60 s with a mass tolerance of 5 ppm. Ions of charge
state 2–7+ were considered. Thermo RAW ﬁles were searched against
the curated UniProt mouse proteome database (release December 2015)
with MaxQuant [52] (version 1.5.1.0) and its integrated search engine
Andromeda. Cysteine carbamidomethyl was used as a ﬁxed modiﬁcation,
and N-terminal acetylation and methionine oxidation were used as
variable modiﬁcations. The mass tolerance for precursor ions was set to
20 ppm and themass tolerance for fragment ions to 0.5 Da. Thematch be-
tween runs feature was enabled and LFQ and IBAQ values were calculated
for each protein. The output Proteingroups ﬁle containing all detected
proteins was loaded into Perseus.[53] Proteins were ﬁrst ﬁltered against a
reverse and contaminant database. Next, the conditions were grouped in
Perseus and any protein that was not detected in all replicates of a single
condition was discarded. Missing values were imputed from the random
distribution with default parameters (width = 0.3, Down shift = 1.8). The
proteins in the resulting list were annotated as chromatin-associated or
not chromatin associated (Table S2, Supporting Information). This was
done by comparing to a list of factors that were experimentally and in
silico determined to be chromatin associated.[33] As this list was gener-
ated in non-pluripotent human cells, we converted the names to mouse
names and we manually included known mouse pluripotency factors.
In addition, we called all zinc ﬁnger proteins chromatin-associated as
these are known to possess nucleic acid binding domains. To speciﬁcally
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identify transcription factors, our detected proteins were matched with
two published lists of murine transcription factors.[44,45] Correlation
between replicates was assessed using spearman correlation. Proteins
that were signiﬁcantly diﬀerent between the conditions were assessed
using ANOVA statistics with Benjamini–Hochberg correction for multiple
testing. Proteins were called signiﬁcant with FDR < 0.05. To calcu-
late p-values in pairwise comparisons in Figure 3B, we used Welch’s
t-test. A list of all detected proteins and whether these are signiﬁcantly
diﬀerent between the conditions can be found in Table S2, Supporting
Information.
For comparison of ChEP with whole cell proteomes, we used whole cell
proteomes that were generated previously in our lab.[54] Downstream anal-
ysis was done with R, Python3, and Jupyter Notebook. GO analysis was
performed using DAVID.[55]
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE partner repository with the
dataset identiﬁer PXD011782.[56]
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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